ArticleCancer discovery2015
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The landscape of GWAS validation; systematic review identifying 309 validated non-coding variants across 130 human diseases.BMC medical genomics · 2022Pooled it
- Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.Health technology assessment (Winchester, England) · 2020Trial
- A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.Nature communications · 2024Article
- Exome Sequence Data of Eight SLC Transporters Reveal ThatPharmaceuticals (Basel, Switzerland) · 2024Article
- Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer.Cancer research · 2023Article
- IsomiR-eQTL: A Cancer-Specific Expression Quantitative Trait Loci Database of miRNAs and Their Isoforms.International journal of molecular sciences · 2022Article
- Integrated Approaches to Identify miRNA Biomarkers Associated with Cognitive Dysfunction in Multiple Sclerosis Using Text Mining, Gene Expression, Pathways, and GWAS.Diagnostics (Basel, Switzerland) · 2022Article
- Genome-Wide 3'-UTR Single Nucleotide Polymorphism Association Study Identifies Significant Prostate Cancer Risk-Associated Functional Loci at 8p21.2 in Chinese Population.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review).Experimental and therapeutic medicine · 2022Review
- Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.Journal of human genetics · 2021Article
- Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper PDK1 in Cancer Metabolism.Cancers · 2021Article
- KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness.Scientific reports · 2021Article
- Inhibition of cancer cell-derived exosomal microRNA-183 suppresses cell growth and metastasis in prostate cancer by upregulating TPM1.Cancer cell international · 2021Article
- Article
- Association of long-chain non-coding RNA GAS5 gene polymorphisms with prostate cancer risk and prognosis in Chinese Han population.Medicine · 2020Article
- Pathway Analysis of Genes Identified through Post-GWAS to Underpin Prostate Cancer Aetiology.Genes · 2020Article
- miR-197-3p Represses the Proliferation of Prostate Cancer by Regulating the VDAC1/AKT/β-catenin Signaling Axis.International journal of biological sciences · 2020Article
- A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms.Cancers · 2019Article
- Assessment by miRNA microarray of an autologous cancer antigen-pulsed adoptive immune ensemble cell therapy (AC-ACT) approach; demonstrated induction of anti-oncogenic and anti-PD-L1 miRNAs.Clinical case reports · 2019Article
- New functions assigned to a microRNA with genetic links to prostate cancer risk.Annals of translational medicine · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
41 authors at 20 institutions in 11 countries.
Shane StegemanAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
Ernest AmankwahDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Kerenaftali KleinStatistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Tracy A O'MaraMolecular Cancer Epidemiology Laboratory, Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Donghwa KimDepartment of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida.
Hui-Yi LinDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
Jennifer Permuth-WeyDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Thomas A SellersDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Srilakshmi SrinivasanAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
Rosalind EelesThe Institute of Cancer Research, London, United Kingdom. Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, United Kingdom.
Doug EastonCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.
Zsofia Kote-JaraiThe Institute of Cancer Research, London, United Kingdom.
Ali Amin Al OlamaCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.
Sara BenllochCentre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.
Kenneth MuirUniversity of Warwick, Coventry, United Kingdom.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Fredrik WiklundDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Henrik GronbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California.
Johanna SchleutkerDepartment of Medical Biochemistry and Genetics, University of Turku, Turku, Finland. Institute of Biomedical Technology/BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
Børge G NordestgaardDepartment of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
David NealSurgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke's Hospital, Cambridge; Cancer Research UK, Cambridge Research Institute, Cambridge, United Kingdom.
Paul PharoahCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Cambridge, United Kingdom.
Kay-Tee KhawCambridge Institute of Public Health, University of Cambridge, Cambridge, United Kingdom.
Janet L StanfordDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington.
William J BlotInternational Epidemiology Institute, Rockville, Maryland.
Stephen ThibodeauMayo Clinic, Rochester, Minnesota.
Christiane MaierDepartment of Urology, University Hospital Ulm, Ulm, Germany. Institute of Human Genetics, University Hospital Ulm, Ulm, Germany.
Adam S KibelBrigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts. Washington University, St. Louis, Missouri.
Cezary CybulskiInternational Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Lisa Cannon-AlbrightDivision of Genetic Epidemiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany.
Radka KanevaMolecular Medicine Center and Department of Medical Chemistry and Biochemistry, Medical University-Sofia, Sofia, Bulgaria.
Manuel R TeixeiraDepartment of Genetics, Portuguese Oncology Institute, Porto; Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal.
PRACTICAL Consortium
Australian Prostate Cancer BioResource
Amanda B SpurdleMolecular Cancer Epidemiology Laboratory, Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Judith A ClementsAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia.
Jong Y ParkDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida.
Jyotsna BatraAustralian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Translational Research Institute, Queensland University of Technology, Brisbane, Australia. jyotsna.batra@qut.edu.au.
Translational Research Institute · AUMoffitt Cancer Center · USMRC Epidemiology Unit · GBQIMR Berghofer Medical Research Institute · AUKarolinska Institutet · SEBridge University · SSCancer Research UK · GBCancer Research UK Cambridge Center · GBGerman Cancer Research Center · DEHerlev Hospital · DKInstituto Português de Oncologia Francisco Gentil · PTInternational Epidemiology Institute · USInternational Hereditary Cancer Center · PLMayo Clinic · USMedical University of Sofia · BGRoyal Marsden NHS Foundation Trust · GBTampere University of Applied Sciences · FIThe University of Melbourne · AUUniversity Hospital Ulm · DEUniversity of Cambridge · GB
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MSouthern Community Cohort StudyR01CA092447 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., ZHENG, WEI · 2001 to 2015
$74.0MEpidemiologic StudiesU19CA148065 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI AHSAN, HABIBUL, BRUGGE, JOAN SIEFERT · 2010 to 2014
$10.6MEpidemiological and Clinical Translational Studies Post Genome-Wide AssociationU19CA148537 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI EASTON, DOUGLAS FREDERICK, EELES, ROSALIND · 2010 to 2014
$10.4MOvarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2MA genome-wide association study for breast cancer in BRCA1 mutation carriersR01CA128978 · NCI · MAYO CLINIC ROCHESTER · PI COUCH, FERGUS JOSEPH · 2008 to 2012
$4.8MIntegrative Molecular Epidemiology WorkshopR25CA174664 · NCI · AMERICAN ASSOCIATION FOR CANCER RESEARCH · PI Shelley S Tworoger · 2013 to 2026
$2.8MGenetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancerR01CA128813 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PARK, JONG Y. · 2008 to 2012
$2.0MMoffitt Postdoctoral Training Program in Molecular & Genetic EpidemiologyR25CA147832 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI EGAN, KATHLEEN M. · 2010 to 2014
$2.0MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 14136Cancer Research UK 15007Cancer Research UK 16491Cancer Research UK 16561Cancer Research UK 16563Cancer Research UK 17528Cancer Research UK 19170Cancer Research UK A10692Cancer Research UK A15007Cancer Research UK A8385Cancer Research UK C12292/A11174Cancer Research UK C1281/A12014Cancer Research UK C1287/A10118Cancer Research UK C1287/A10710Cancer Research UK C5047/A10692Cancer Research UK C5047/A15007Cancer Research UK C5047/A8384CIHRMedical Research Council G0401527Medical Research Council G1000143NCI NIH HHS 1U19 CA148065NCI NIH HHS 1U19 CA148112NCI NIH HHS 1U19 CA148537NCI NIH HHS CA128978NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA092447NCI NIH HHS R01 CA128813NCI NIH HHS R01 CA128978NCI NIH HHS R25 CA147832NCI NIH HHS R25 CA174664NCI NIH HHS U19 CA148065NCI NIH HHS U19 CA148112NCI NIH HHS U19 CA148537
Abstract
unlabelledProstate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role. SIGNIFICANCE: Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk.
Indexed as
Binding SitesGenetic Variation3' Untranslated RegionsAdultAgedAllelesCase-Control StudiesCluster AnalysisGene Expression ProfilingGene Expression Regulation, NeoplasticGenotypeHumansKallikreinsMaleMicroRNAsMiddle Aged3' Untranslated RegionsKallikreinsKLK3 protein, humanMicroRNAsProstate-Specific AntigenRNA, MessengerR-SNARE ProteinsVAMP8 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.